Editas Medicine said the USPTO reaffirmed an earlier Patent Trial and Appeal Board decision supporting Broad Institute inventorship priority for foundational CRISPR/Cas9 genome editing patents in eukaryotic cells, including human cells. The dispute, originally decided in 2022, centers on first-in-inventor priority for CRISPR/Cas9 use and involves Broad, MIT, Harvard, the University of California, the University of Vienna, and Emmanuelle Charpentier. Editas noted that other in-licensed Broad patents covering CRISPR/Cas9 and CRISPR/Cas12a remain unaffected by this specific interference outcome. The company framed the decision as reinforcing confidence in its intellectual property while it develops EDIT-401, which it says has achieved more than 90% mean LDL cholesterol reduction in non-human primates. The USPTO’s reaffirmation keeps the priority question in Broad’s favor, shaping the risk calculus for CRISPR therapeutics developers navigating licensing and freedom-to-operate constraints.